Evidence map›Paper›PMID 31289792›Full record

ArticleCytokine: X2019

MIF mediates bladder pain, not inflammation, in cyclophosphamide cystitis.

Fei Ma, Dimitrios E Kouzoukas, Katherine L Meyer-Siegler, David E Hunt, Lin Leng, Richard Bucala, Pedro L Vera

Open access · hybridAbstract read
In one paragraph

Article in Cytokine: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Suppression of Inflammatory and Fibrotic Signals by Cinnamon (Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Fei MaResearch and Development, Lexington Veterans Affairs Health Care System, Lexington, Kentucky, United States of America.
Dimitrios E KouzoukasResearch and Development, Lexington Veterans Affairs Health Care System, Lexington, Kentucky, United States of America.
Katherine L Meyer-SieglerDepartment of Natural Sciences, St. Petersburg College, St. Petersburg, Florida, United States of America.
David E HuntResearch and Development, Lexington Veterans Affairs Health Care System, Lexington, Kentucky, United States of America.
Lin LengDepartment of Internal Medicine, Yale University, New Haven, Connecticut, United States of America.
Richard BucalaDepartment of Internal Medicine, Yale University, New Haven, Connecticut, United States of America.
Pedro L VeraResearch and Development, Lexington Veterans Affairs Health Care System, Lexington, Kentucky, United States of America.
Lexington VA Health Care System · USYale University · USSt. Petersburg College · USUniversity of Kentucky · US

Funding

Mechanisms of Rheumatoid Synovial Fibroblast ActivationR01AR049610 · NIAMS · YALE UNIVERSITY · PI BUCALA, RICHARD J · 2002 to 2018
$5.0M
MIF: a pro-inflammatory cytokine as a novel target to reduce bladder inflammationR01DK093496 · NIDDK · LEXINGTON BIOMEDICAL RESEARCH INSTITUTE · PI VERA, PEDRO L · 2012 to 2016
$1.2M
NIAMS NIH HHS R01 AR049610NIDDK NIH HHS R01 DK093496
6 · The paper itself

Abstract

Macrophage migration inhibitory factor (MIF), a proinflammatory mediator, is recognized as a player in inflammatory and neuropathic pain. Cyclophosphamide (CYP) results in bladder inflammation and pain and it's a frequently used animal model of interstitial cystitis/bladder pain syndrome (IC/BPS). Because pretreatment with a MIF inhibitor (ISO-1) prevented both CYP-induced bladder pain and inflammation we used genetic MIF knockout (KO) mice to further investigate MIF's role in CYP-induced bladder pain and inflammation. Abdominal mechanical threshold measured bladder pain induced by CYP in wild type (WT) and MIF KO mice at several time points (0-48 hours). End-point (48 hours) changes in micturition parameters and histological signs of bladder inflammation were also evaluated. Abdominal mechanical hypersensitivity developed within 4 hours after CYP injection (and lasted for the entire observation period: 48 hours) in WT mice. MIF KO mice, on the other hand, did not develop abdominal mechanical hypersensitivity suggesting that MIF is a pivotal molecule in mediating CYP-induced bladder pain. Both WT and MIF KO mice treated with CYP showed histological signs of marked bladder inflammation and showed a significant decrease in micturition volume and increase in frequency. Since both changes were blocked in MIF KO mice by pretreatment with a MIF inhibitor (ISO-1) it is likely these are non-specific effects of ISO-1. MIF mediates CYP-induced bladder pain but not CYP-induced bladder inflammation. The locus of effect (bladder) or central (spinal) for MIF mediation of bladder pain remains to be determined.

Indexed as

bladder painCYPERKISO-1MIF

Identifiers

PMID31289792
PMCPMC6615480
OpenAlexW2911896621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.